Overview

Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

Phase II trial to determine the efficacy of Dose Adjusted-EPOCH-Rituximab regimen in children and adolescent with primary mediastinal large B cell lymphoma in terms of event free survival.

Phase:

Phase 2

Details

Lead Sponsor:

Gustave Roussy, Cancer Campus, Grand Paris

Collaborator:

Children's Oncology Group

Treatments:

Cyclophosphamide
Doxorubicin
Etoposide
Rituximab
Vincristine